ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
miR-138-5p inhibits WiT-49 cell growth in vitro by downregulating TCF3 expression, and suppresses tumorigenesis in vivo.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposemiR-138-5p plays a tumor-suppressing role, but its function in Wilms tumor (WT) has not yet been explored. This study aimed to investigate the role of miR-138-5p in the progression of WT.
methodsHematoxylin‒eosin staining was used to analyze histopathological changes in WT tissues and adjacent normal tissues. qPCR was used to detect the expression of miR-138-5p in WT tissues and cells. Immunohistochemical staining and qPCR were used to detect the expression of TCF3. The interaction between miR-138-5p and TCF3 was confirmed by correlation analysis, qPCR, and dual-luciferase assays, respectively. CCK-8, colony formation, Transwell, and wound-healing assays were performed to identify the effects of miR-138-5p and TCF3 on the proliferation and migration of WiT49 cells. A murine xenograft model was used to investigate the function of miR-138-5p on WT growth in vivo.
resultsmiR-138-5p was expressed at low levels in WT tissues and WiT-49 cells. Functional studies demonstrated that the upregulation of miR-138-5p markedly inhibited the proliferation, colony-formation capacity, and migratory/invasive potential of WiT-49 cells. Subsequently, the therapeutic potential of miR-138-5p overexpression was confirmed in murine xenograft models, which markedly inhibited tumor growth compared with that in the control group. TCF3 is a target of miR-138-5p, and its expression is negatively correlated with that of miR-138-5p. Furthermore, the results of rescue experiments indicated that the tumor-suppressing effects of miR-138-5p in WiT-49 cells were reversed by TCF3 overexpression.
conclusionsmiR-138-5p could be a tumor suppressor that regulates the proliferation of WT cells by targeting and reducing TCF3 expression.
Indexed as
Identifiers
42053744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.